Title: mometasone, Elocon
Category: Medications
Created: 12/31/1997
Last Editorial Review: 7/31/2009

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT ), a development-stage oncology and dermatology biopharmaceutical company, has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. After reviewing safety and efficacy data from its PH-10 trial for atopic dermatitis, Provectus determined that daily dosing of patients with psoriasis trial would be an appropriate and attractive regimen.

California and Arizona researchers have identified a gene variant that carries nearly twice the risk of developing an increasingly common type of blood cancer, according to a study published online by the science journal Nature Genetics.

Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.

Many of the approximately one million Canadians(i) living with psoriasis may be faced with physical or emotional challenges as they struggle with public misperceptions and stigmas of this painful, chronic immune disorder that affects the skin. Now, a Leger Marketing survey of Canadians with psoriasis, pSoriasis Knowledge IN Canada (SKIN), reveals that the debilitating skin condition presents a substantial problem for them in their daily lives.